(321) 305-5015
Merritt Island Medical Research
  • Home
  • Current Indications
  • Interesting reads
  • Sponsors and CROs
  • Contact Us
Select Page

Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease

by Josh | Aug 24, 2023 | PRN Newswire

Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB) Phase 3 trial met primary endpoint and all secondary endpoints measuring cognitive and functional decline Donanemab...

Recent Posts

  • P-Tau 217 Continues to Show Benefit as Predictor of Cognitive Decline in Preclinical Alzheimer Disease
  • Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease
  • New study hints at why infamous gene variant increases odds of developing Alzheimer’s disease
  • The single best type of exercise for your brain, according to scientists
  • Why Playing a Musical Instrument Can Protect Brain Health

Recent Comments

    Archives

    • August 2023
    • August 2017
    • May 2017
    • April 2017

    Categories

    • Neurology Live
    • PRN Newswire
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Facebook
    • Twitter
    • RSS

    Designed by Elegant Themes | Powered by WordPress